These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 11733188)
1. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. Pasheva EA; Ugrinova I; Spassovska NC; Pashev IG Int J Biochem Cell Biol; 2002 Jan; 34(1):87-92. PubMed ID: 11733188 [TBL] [Abstract][Full Text] [Related]
2. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts. Malina J; Kasparkova J; Natile G; Brabec V Chem Biol; 2002 May; 9(5):629-38. PubMed ID: 12031669 [TBL] [Abstract][Full Text] [Related]
3. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. Yaneva J; Leuba SH; van Holde K; Zlatanova J Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13448-51. PubMed ID: 9391045 [TBL] [Abstract][Full Text] [Related]
4. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. Kaspárková J; Brabec V Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982 [TBL] [Abstract][Full Text] [Related]
5. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes. Novakova O; Kasparkova J; Malina J; Natile G; Brabec V Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903 [TBL] [Abstract][Full Text] [Related]
6. Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. Kostrhunova H; Malina J; Pickard AJ; Stepankova J; Vojtiskova M; Kasparkova J; Muchova T; Rohlfing ML; Bierbach U; Brabec V Mol Pharm; 2011 Oct; 8(5):1941-54. PubMed ID: 21806015 [TBL] [Abstract][Full Text] [Related]
7. Toxicity of platinum(II) amino acid (N,O) complexes parallels their binding to DNA as measured in a new solid phase assay involving a fluorescent HMG1 protein construct readout. Ziegler CJ; Sandman KE; Liang CH; Lippard SJ J Biol Inorg Chem; 1999 Aug; 4(4):402-11. PubMed ID: 10555574 [TBL] [Abstract][Full Text] [Related]
8. DNA binding studies with cis-dichlorobis (5(6)-non/chlorosubstituted-2-hydroxymethyl-benzimidazole) platinum(II) complexes. Gümüş F; Algül O J Inorg Biochem; 1997 Oct; 68(1):71-4. PubMed ID: 9379182 [TBL] [Abstract][Full Text] [Related]
9. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158 [TBL] [Abstract][Full Text] [Related]
10. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues. Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968 [TBL] [Abstract][Full Text] [Related]
11. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126 [TBL] [Abstract][Full Text] [Related]
12. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. Chow CS; Barnes CM; Lippard SJ Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709 [TBL] [Abstract][Full Text] [Related]
13. Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA. Park S; Lippard SJ Biochemistry; 2011 Apr; 50(13):2567-74. PubMed ID: 21355578 [TBL] [Abstract][Full Text] [Related]
14. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex. Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702 [TBL] [Abstract][Full Text] [Related]
16. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Mello JA; Acharya S; Fishel R; Essigmann JM Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. Brabec V; Kasparkova J; Kostrhunova H; Farrell NP Sci Rep; 2016 Aug; 6():28474. PubMed ID: 27574114 [TBL] [Abstract][Full Text] [Related]
18. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA. Jamieson ER; Lippard SJ Biochemistry; 2000 Jul; 39(29):8426-38. PubMed ID: 10913248 [TBL] [Abstract][Full Text] [Related]
19. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Brabec V Prog Nucleic Acid Res Mol Biol; 2002; 71():1-68. PubMed ID: 12102553 [TBL] [Abstract][Full Text] [Related]
20. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B. Jamieson ER; Jacobson MP; Barnes CM; Chow CS; Lippard SJ J Biol Chem; 1999 Apr; 274(18):12346-54. PubMed ID: 10212205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]